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ABSTRACT 
 
Objective: To estimate the patient-specific risk of preeclampsia (PE) at 30-34 weeks’ 
gestation by a combination of maternal characteristics and medical history with multiple of 
the median (MoM) values of mean arterial pressure, uterine artery pulsatility index, serum 
placental growth factor and serum soluble fms-like tyrosine kinase-1 and stratify women 
into high-, intermediate- and low-risk management groups. 
 
Methods: This was a prospective observational study in women attending for a 
third-trimester ultrasound scan at 30-34 weeks as part of routine pregnancy care. 
Patient-specific risks of delivery with PE at <4 weeks from assessment and at <40 weeks’ 
gestation were calculated using the competing risks model to combine the prior risk from 
maternal characteristics and medical history with MoM values of MAP, UTPI, PLGF and 
sFLT-1. On the basis of these risks the population was stratified into high-, intermediate- 
and low-risk groups. Different risk cut-offs were used to vary the proportion of the 
population stratified into each risk category and the performance of screening for delivery 
with PE at <4 weeks and delivery with PE from four weeks after assessment and up to 40 
weeks’ gestation (PE 4w-40GW) was estimated.  
 
Results: The study population of 8,128 singleton pregnancies included 234 (2.9%) that 
subsequently developed PE. Using a risk cut-off for PE at <4 weeks of 1 in 50 and a risk 
cut-off of 1 in 150 for PE at <40 weeks’ gestation the proportion of the population stratified 
into high-, intermediate- and low-risk was about 3%, 26% and 71%, respectively. The 
high-risk group contained 90% of pregnancies with PE at <4 weeks and 40% of those 
with PE at 4w-40GW. The intermediate-risk group contained a further 49% of women with 
PE at 4w-40GW. In the low-risk group, none of the women developed PE at <4 weeks 
and only 0.3% developed PE at 4w-40GW.   
 
Conclusion: The study presents risk stratification of PE by the combined test at 30-34 
weeks aiming to identify a high-risk group in need of intensive monitoring from the time of 
the initial assessment and up to 40 weeks’ gestation and an intermediate-risk group, in 
need of monitoring starting from four weeks after the initial assessment and up to 40 
weeks’ gestation. All pregnancies would need to be reassessed at 40 weeks’ gestation.    
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Introduction 
 
The objectives of screening for preeclampsia (PE) are firstly, to reduce the prevalence of 
the disease through pharmacological intervention in the high-risk group identified in the 
first-trimester of pregnancy 1,2 and secondly, to minimize adverse perinatal events for 
those that develop PE by determining the appropriate time and place for delivery 3. The 
second objective can be potentially achieved through risk stratification in the second and / 
or third-trimester of pregnancy.  
 
A study in 8,128 pregnancies at 30-34 weeks’ gestation reported that screening by a 
combination of maternal factors with multiples of the median (MoM) values of mean 
arterial pressure (MAP), uterine artery pulsatility index (UTPI), serum placental growth 
factor (PLGF) and serum soluble fms-like tyrosine kinase-1 (sFLT-1) predicted 98% of 
pregnancies that developed PE and delivered at <37 weeks’ gestation and 49% of those 
with PE at >37 weeks, at 5% false positive rate 4.  
 
The objective of this study is to estimate the patient-specific risk of PE at 30-34 weeks’ 
gestation by a combination of maternal characteristics and medical history with MAP, 
UTPI, PLGF and sFLT-1 and stratify women into high-, intermediate- and low-risk 
management groups. 
 
 
Methods 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for a third-trimester routine hospital visit at King’s College 
Hospital, London or Medway Maritime Hospital, Gillingham, UK between March 2012 and 
January 2014. In this visit at 30+0-34+6 weeks’ gestation we first, recorded maternal 
demographic characteristics and medical history, second, carried out an ultrasound 
examination for fetal anatomy and growth, third, measured the left and right UTPI by 
transabdominal color Doppler ultrasound and calculated the mean value of the two 
arteries 5, fourth, measured the MAP by validated automated devices and a standardized 
protocol 6 and fifth, measured serum concentration of PLGF and sFLT-1 by an automated 
biochemical analyzer within 10 minutes of blood sampling (Cobas e411 system, Roche 
Diagnostics, Penzberg, Germany). Gestational age was determined by the measurement 
of fetal crown-rump length at 11-13 weeks or the fetal head circumference at 19-24 weeks 
7,8.  
 
The women gave written informed consent to participate in the study, which was 
approved by the NHS Research Ethics Committee. The inclusion criteria for this study 
were singleton pregnancies delivering a non-malformed live birth or stillbirth at >30 
weeks’ gestation. We excluded pregnancies with aneuploidies and major fetal 
abnormalities. The study population is the same as in our previous report.4 
 
Data on pregnancy outcome were collected from the hospital maternity records or the 
general medical practitioners of the women. The obstetric records of all women with 
pre-existing or pregnancy associated hypertension were examined to determine if the 
condition was PE, as defined by the International Society for the Study of Hypertension in 
Pregnancy 9.  
 
In order to focus clinical resources effectively, we investigated a policy whereby 
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pregnancies assessed for PE at 30-34 weeks are stratified into three groups (Figure 1). A 
group at high-risk for delivery with PE within 4 weeks of assessment (PE <4 weeks), 
would require intensive monitoring from the time of the initial assessment and up to 40 
weeks’ gestation; this group should be ideally small and contain a large proportion of 
pregnancies with PE at <4 weeks. Conversely, the low-risk group, that would be 
reassessed only at 40 weeks’ gestation, should be large and contain very few 
pregnancies that develop PE at <40 weeks’ gestation. The intermediate-risk group, would 
ideally contain very few pregnancies with PE at <4 weeks and a large proportion of 
pregnancies that deliver with PE from four weeks after assessment and up to 40 weeks’ 
gestation (PE 4w-40GW); this group would require reassessment after four weeks or 
intensive monitoring starting from four weeks after the initial assessment and up to 40 
weeks’ gestation.  
 
Statistical analysis 
 
Patient-specific risks of delivery with PE at <4 weeks from assessment and at <40 weeks’ 
gestation were calculated using the competing risks model to combine the prior risk for 
PE from maternal characteristics and medical history with MoM values of MAP, UTPI, 
PLGF and sFLT-1.4,10-15 Pregnancies were allocated to the high-risk group if their risk for 
PE at <4 weeks was above a specific high-risk threshold and they were allocated to the 
low-risk group if their risk for PE at <40 weeks’ gestation was below a specified low-risk 
threshold. Otherwise, they were allocated to the intermediate risk group. Performance 
was assessed in terms of the distribution of pregnancy outcomes by risk group.     
 
The statistical software package R was used for data analyses.16 
 
 
Results 
 
The study population of 8,128 singleton pregnancies included 234 (2.9%) that 
subsequently developed PE. Maternal and pregnancy characteristics of the study 
population are summarized in Table 1. The allocation of pregnancies to risk group by 
pregnancy outcome are given in Table 2.  
 
Delivery with PE at <4 weeks 
 
In the study population there were 31 pregnancies that developed PE and were delivered 
within four weeks from assessment. At risk cut-off of 1 in 3 for PE at <4 weeks from 
assessment, 77.4% of pregnancies with PE at <4 weeks were allocated to the high-risk 
group which comprised of 0.9% of all pregnancies. The respective values for risk cut-off 
of 1 in 10 were 83.9 and 1.6%, for cut-off of 1 in 50 they were 90.3 and 3.1%, for cut-off of 
1 in 100 they were 90.3 and 3.9% and for cut-off of 1 in 150 they were 93.5 and 4.5%.  
 
Consequently, the proportion of the population that would require intensive monitoring 
from the time of the initial assessment and up to 40 weeks’ gestation would increase from 
0.9% if the risk cut-off was 1 in 3 to 4.5% if the cut-off was 1 in 150 and the proportion of 
pregnancies with PE at <4 weeks in the high-risk group would increase from 77.5% to 
93.5% 
 
Delivery with PE at 4w-40GW 
 
5 
 
In the study population there were 141 pregnancies that delivered with PE at 4w-40GW. 
The allocation of these cases into the high-, intermediate- and low-risk groups is shown in 
Table 2.  
 
For example, the high-risk group defined by a risk cut-off of 1 in 50 for PE at <4 weeks 
constituted 3.1% of the population and contained 40.47% (57/141) of pregnancies with 
PE at 4w-40GW. Using this risk cut-off of 1 in 50 for PE at <4 weeks and a risk cut-off of 1 
in 150 for PE at <40 weeks’ gestation, 26.4% of pregnancies were allocated to the 
intermediate-risk group which contained 48.9% (69/141) of pregnancies with PE at 
4w-40GW. Consequently, for these particular risk cut-offs, 29.5% of pregnancies were 
allocated to the high- or intermediate-risk group and the combination of these groups 
contained a total of 89.4% (126/141) of pregnancies with PE at 4w-40GW. 
 
Delivery with PE at >40GW 
 
In the study population there were 62 pregnancies that delivered with PE at >40GW. The 
allocation of these cases into the high-, intermediate- and low-risk groups is shown in 
Table 2. For example, the high-risk group defined by a risk cut-off of 1 in 50 for PE at <4 
weeks constituted 3.1% of the population and contained 11.3% (7/62) of pregnancies with 
PE at >40GW. Using this risk cut-off of 1 in 50 for PE at <4 weeks and a risk cut-off of 1 in 
150 for PE at <40 weeks’ gestation, 26.4% of pregnancies were allocated to the 
intermediate-risk group which contained 56.5% (35/62) of pregnancies with PE at >40GW. 
Consequently, for these particular risk cut-offs, 29.5% of pregnancies were allocated to 
the high- or intermediate-risk group and the combination of these groups contained a total 
of 67.7% (42/62) of pregnancies with PE at >40GW; the remaining 70.5% of pregnancies 
were allocated to the low-risk group which contained 32.3% of pregnancies with PE 
at >40GW. 
 
The performance of screening for delivery with PE at >40GW is poorer than that of 
screening for delivery with PE at <4 weeks or at 4w-40GW (Figure 2). This is the 
consequence of lower deviation from normal for each biomarker with increasing interval 
between assessment and delivery with PE.4 
 
Composition of the high-, intermediate- and low-risk groups 
 
The proportion of the population stratified into high- intermediate- and low-risk groups for 
risk cut-offs of 1 in 3, 1 in 10, 1 in 50, 1 in 100 and 1 in 150 for PE at <4 weeks from 
assessment and cut-off of 1 in 150 for PE at <40 weeks’ gestation and the proportion of 
each strata developing PE with delivery at <4 weeks, at 4w-40GW and at >40GW is 
shown in Table 3. 
 
In the low-risk group, which accounted for 70.5% of the population, there were no cases 
of PE at <4 weeks and only 0.3% developed PE at 4w-40GW; therefore, the negative 
predictive value for PE at <4 weeks was 100% (5727/5727) and for PE at 4w-40GW was 
99.7% (5712/5727). 
 
The proportion of the population classified as high-risk varied according to the risk cut-off 
for PE at <4 weeks from 0.9% for cut-off of 1 in 3 to 4.5% for cut-off of 1 in 150 and the 
positive predictive value for PE at <4 weeks ranged from 31.6% (24/76) to 7.9% (29/369). 
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The proportion of the population classified as intermediate-risk varied according to both 
the risk cut-off for PE at <4 weeks and the cut-off for PE at <40 weeks’ gestation. For 
example, at fixed risk cut-off of 1 in 150 for PE at <40 weeks’ gestation, the proportion of 
the population classified as intermediate-risk varied according to the risk cut-off for PE at 
<4 weeks from 28.6% for risk cut-off of 1 in 3 to 25.0% for risk cut-off of 1 in 150; the 
positive predictive value for PE at 4w-40GW ranged from 4.3% (101/2325) to 2.9% 
(58/2032) and the negative predictive value for PE at <4 weeks ranged from 99.7% 
(2318/2325) to 99.9% (2030/2032). 
 
 
Discussion 
 
Main findings 
 
The study has demonstrated an approach for stratification of the population into three 
management groups based on the estimated risk for PE at <4 weeks from assessment 
and at <40 weeks’ gestation by a combination of maternal factors, MAP, UTPI, PLGF and 
sFLT-1 at 30-34 weeks’ gestation. A high-risk group would require intensive monitoring 
from the time of the initial assessment and up to 40 weeks’ gestation, an intermediate-risk 
group would require intensive monitoring starting from four weeks after the initial 
assessment and up to 40 weeks’ gestation and a low-risk group would be reassessed 
only at 40 weeks’ gestation. The performance of screening at 30-34 weeks is poor for 
prediction of PE at >40 weeks’ gestation and it would therefore be necessary to reassess 
all remaining pregnancies at 40 weeks to decide the best time and method of delivery.       
 
The proportion of the population stratified into high- intermediate- and low-risk groups and 
the proportion of each strata developing PE with delivery at <4 weeks, at 4w-40GW and 
at >40GW would inevitably depend on the risk cut-offs used for defining the groups. At 
risk cut-offs of 1 in 50 for PE at <4 weeks and 1 in 150 for PE at <40 weeks’ gestation, 
about 3% and 26% of the population would be allocated to the high- and intermediate-risk 
groups, respectively; the high-risk group would contain 90% of pregnancies with PE at <4 
weeks and the combined high- and intermediate-risk groups would contain 89% of PE at 
4w-40GW and 68% of PE at >40GW. At these risk cut-offs the low-risk group accounted 
for 71% of the population and in this group there were no cases of PE at <4 weeks and 
only 0.3% developed PE at 4w-40GW, which corresponds to a negative predictive value 
of 99.7%. 
 
Strengths and limitations 
 
The strengths of this study are first, examination of a large population of pregnant women 
attending for routine care in a gestational age range which is widely used for assessment 
of fetal growth and wellbeing, second, recording of data on maternal characteristics and 
medical history to define the prior risk, third, use of a specific methodology and 
appropriately trained doctors to measure MAP and UTPI, fourth, use of automated 
machines to provide accurate measurement within 40 minutes of sampling of maternal 
serum concentration of PLGF and sFLT-1, fifth, expression of the values of the 
biomarkers as MoMs after adjustment for factors that affect the measurements, and sixth, 
use of Bayes theorem to combine the prior risk from maternal factors with biomarkers to 
estimate patient-specific risks and stratify women into high-, intermediate- and low-risk 
management groups. 
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A limitation of the study is that fitting of the risk model4 and development and assessment 
of risk stratification were on the same data, which induces a degree of optimistic bias into 
the results. However, our risk model4 is a parsimonious one with just two parameters for 
the mean log MoM value for each of the markers and a pooled estimate of an assumed 
common covariance matrix and this limits the degree of bias induced. Nevertheless, 
prospective evaluation using an independent test data set is needed to validate the 
results.   
 
Comparison with previous studies 
 
Previous studies examining biomarkers in the late second- or early third-trimesters of 
pregnancy have essentially focused on the investigation of women presenting to 
specialist clinics with signs of hypertensive disorders with the aim of identifying the 
subgroup that will develop severe disease.17-24 In a previous study at 30-34 weeks’ 
gestation we presented the results on the performance of screening in a routine 
population by maternal factors and MAP, UTPI, PLGF and sFLT-1. 4 This study 
investigated a policy whereby pregnancies assessed for PE at 30-34 weeks are stratified 
into risk groups for subsequent pregnancy management.  
 
Clinical implications of the study 
 
In the traditional approach to prenatal care, screening and diagnosis of PE is based on 
the demonstration of elevated blood pressure and proteinuria during a routine clinical visit 
in the late second- or third-trimester of pregnancy. In a proposed new pyramid of 
pregnancy care, the timing and content of clinical visits should be defined by the 
patient-specific risk of developing PE.25  
 
This study provides the framework for stratification of risk for PE based on screening at 
30-34 weeks. The high-risk group can be monitored by measurement of blood pressure 
and urinalysis at least on a weekly basis and the women can be advised to report any of 
the symptoms associated with severe PE, such as visual disturbance and epigastric pain. 
In the intermediate-risk group, intensive monitoring would begin four weeks after the 
initial assessment but these women would also be advised to report any symptoms 
associated with severe PE. The low-risk group can be reassured that development of PE 
at <40 weeks’ gestation is very unlikely. In all pregnancies, the routine ultrasound 
examination carried out at 30-34 weeks would have already identified any possible 
impairment of fetal growth and in such case the decision on timing of delivery would be 
based on fetal heart rate patterns and / or Doppler findings in the umbilical artery, middle 
cerebral artery and ductus venosus.  
 
The cut-offs in risks to define the proportion of the population stratified into each of the 
three management groups and the protocols for such management will inevitably vary 
according to local preferences and health economic considerations. Future studies will 
examine whether the implementation of such protocols could improve perinatal outcome. 
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Figure legends 
 
Figure 1. Stratification of pregnancies into high-, intermediate- and low-risk management 
groups based on the estimated risk for preeclampsia at 30-34 weeks’ gestation. The 
high-risk group would require intensive monitoring from the time of the initial assessment 
and up to 40 weeks’ gestation, the intermediate-risk group would require intensive 
monitoring starting from four weeks after the initial assessment and up to 40 weeks’ 
gestation and the low-risk group would be reassessed only at 40 weeks’ gestation.  
 
Figure 2. Receiver operating characteristic curves for prediction of delivery with 
preeclampsia within four weeks of assessment (left) and delivery with preeclampsia from 
four weeks after assessment and up to 40 weeks’ gestation (right red line) and delivery 
with preeclampsia after 40 weeks (right blue) by combined screening at 30-34 weeks’ 
gestation. 
12 
 
Table 1. Maternal and pregnancy characteristics in pregnancies that developed 
preeclampsia (PE) within four weeks from assessment, at four weeks from 
assessment and up to 40 weeks’ gestation and at >40 weeks’ gestation, compared 
with pregnancies that remained normotensive. 
 
Maternal characteristics 
Preeclampsia 
None 
(n=7,894) 
<4 weeks 
(n=31) 
4 w-40GW 
(n=141) 
>40GW 
(n=62) 
Age, median (IQR) 31.0 (26.7-34.7) 31.0 (26.3-34.2) 31.7 (27.5-35.2) 31.0 (24.8-34.8) 
Weight, median (IQR) 67.2 (59.4-78.0) 70.4 (60.0-86.0) 76.0 (64.5-89.9) 69.0 (60.2-84.9) 
Height, median (IQR) 1.65 (1.60-1.69) 1.60 (1.58-1.65) 1.65 (1.60-1.69) 1.64 (1.60-1.69) 
Racial origin     
     Caucasian, n (%) 5,923 (75.0) 20 (64.5) 80 (56.7) 42 (67.7) 
     Afro-Caribbean, n (%) 1,353 (17.1) 9 (29.0) 50 (35.5) 17 (27.4) 
     South Asian, n (%) 297 (3.8) 2 (6.5) 6 (4.3) 2 (3.2) 
     East Asian, n (%) 145 (1.8) 0 3 (2.1) 1 (1.6) 
     Mixed, n (%) 176 (2.2) 0 2 (1.4) 0 
Method of conception     
     Spontaneous, n (%) 7,631 (96.7) 29 (93.5) 136 (96.5) 60 (96.8) 
     Assisted conception, n (%) 263 (3.3) 2 (6.5) 5 (3.5) 2 (3.2) 
Cigarette smoking, n (%) 798 (10.1) 1 (3.2) 8 (5.7) 4 (6.5) 
Chronic hypertension, n (%) 90 (1.1) 6 (19.4) 23 (16.3) 3 (4.8) 
SLE / APS, n (%) 15 (0.2) 0 0 0 
Diabetes mellitus, n (%) 77 (1.0) 0 3 (2.1) 0 
Parity     
     Nulliparous, n (%) 3,871 (49.0) 20 (64.5) 68 (48.2) 48 (77.4) 
     Parous no previous PE, n (%) 3,752 (47.5) 8 (25.8) 42 (29.8) 13 (21.0) 
     Parous previous PE, n (%) 271 (3.4) 3 (9.7) 31 (22.0) 1 (1.6) 
Family history of PE, n (%) 235 (3.0) 1 (3.2) 6 (4.3) 2 (3.2) 
Inter-pregnancy interval, median (IQR)* 3.1 (2.1-5.1) 7.1 (3.5-8.2) 3.6 (2.4-5.3) 6.6 (2.7-9.0) 
 
* Inter-pregnancy interval reported for parous women 
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Risk cut off for PE 
Preeclampsia with delivery at: All pregnancies 
(n=8128) 
  <4 w (n=31)  4 w to 40 GW (n=141) >40 GW (n=62) 
1 in 3 for PE <4 w 24 (77.4; 58.9, 90.4) 25 (17.7; 11.8, 25.1) 0 (0.0; 0.0, 5.8) 76 (0.9; 0.7, 1.2) 
1 in 50 for PE <40 GW 6 (19.4; 7.5, 37.5) 81 (57.4; 48.8, 65.7) 26 (41.9; 29.5, 55.2) 1141 (14.0; 13.3, 14.8) 
1 in 100 for PE <40 GW 7 (22.6; 9.6, 41.1) 95 (67.4; 59.0, 75.0) 37 (59.7; 46.4, 71.9) 1828 (22.5; 21.6, 23.4) 
1 in 150 for PE <40 GW 7 (22.6; 9.6, 41.1) 101 (71.6; 63.4, 78.9) 42 (67.7; 54.7, 79.1) 2325 (28.6; 27.6, 29.6) 
1 in 200 for PE <40 GW 7 (22.6; 9.6, 41.1) 104 (73.8; 65.7, 80.8) 44 (71.0; 58.1, 81.8) 2774 (34.1; 33.1, 35.2) 
1 in 10 for PE <4 w 26 (83.9; 66.3, 94.5) 37 (26.2; 19.2, 34.3) 1 (1.6; 0.0, 8.7) 134 (1.6; 1.4, 1.9) 
1 in 50 for PE <40 GW 4 (12.9; 3.6, 29.8) 69 (48.9; 40.4, 57.5) 25 (40.3; 28.1, 53.6) 1083 (13.3; 12.6, 14.1) 
1 in 100 for PE <40 GW 5 (16.1; 5.5, 33.7) 83 (58.9; 50.3, 67.1) 36 (58.1; 44.8, 70.5) 1770 (21.8; 20.9, 22.7) 
1 in 150 for PE <40 GW 5 (16.1; 5.5, 33.7) 89 (63.1; 54.6, 71.1) 41 (66.1; 53.0, 77.7) 2267 (27.9; 26.9, 28.9) 
1 in 200 for PE <40 GW 5 (16.1; 5.5, 33.7) 92 (65.2; 56.8, 73.1) 43 (69.4; 56.3, 80.4) 2716 (33.4: 32.4, 34.5) 
1 in 50 for PE <4 w 28 (90.3; 74.2, 98.0) 57 (40.4; 32.3, 49.0) 7 (11.3; 4.7, 21.9) 254 (3.1; 2.8, 3.5) 
1 in 50 for PE <40 GW 2 (6.5; 0.8, 21.4) 49 (34.8; 26.9, 43.2) 19 (30.6; 19.6, 43.7) 963 (11.8; 11.2, 12.6) 
1 in 100 for PE <40 GW 3 (9.7; 2.0, 25.8) 63 (44.7; 36.3, 53.3) 30 (48.4; 35.5, 61.4) 1650 (20.3; 19.4, 21.2) 
1 in 150 for PE <40 GW 3 (9.7; 2.0, 25.8) 69 (48.9; 40.4, 57.5) 35 (56.5; 43.3, 69.0) 2147 (26.4; 25.5, 27.4) 
1 in 200 for PE <40 GW 3 (9.7; 2.0, 25.8) 72 (51.1; 42.5, 59.6) 37 (59.7; 46.4, 71.9) 2596 (31.9; 30.9, 33.0) 
1 in 100 for PE <4 w 28 (90.3; 74.2, 98.0) 64 (45.4; 37.0, 54.0) 8 (12.9; 5.7, 23.9) 314 (3.9; 3.5, 4.3) 
1 in 50 for PE <40 GW 2 (6.5; 0.8, 21.4) 42 (29.8; 22.4, 38.1) 18 (29.0; 18.2, 41.9) 903 (11.1; 10.4, 11.8) 
1 in 100 for PE <40 GW 3 (9.7; 2.0, 25.8) 56 (39.7; 31.6, 48.3) 29 (46.8; 34.0, 59.9) 1590 (19.6; 18.7, 20.4) 
1 in 150 for PE <40 GW 3 (9.7; 2.0, 25.8) 62 (44.0; 35.6, 52.6) 34 (54.8; 41.7, 67.5) 2087 (25.7; 24.7, 26.6) 
1 in 200 for PE <40 GW 3 (9.7; 2.0, 25.8) 65 (46.1; 37.7, 54.7) 36 (58.1; 44.8, 70.5) 2536 (31.2; 30.2, 32.2) 
1 in 150 for PE <4 w 29 (93.5; 78.6, 99.2) 68 (48.2; 39.7, 56.8) 11 (17.7; 9.2, 29.5) 369 (4.5; 4.1, 5.0) 
1 in 50 for PE <40 GW 1 (3.2; 0.1, 16.7) 38 (27.0; 19.8, 35.1) 15 (24.2; 14.2, 36.7) 848 (10.4; 9.8, 11.1) 
1 in 100 for PE <40 GW 2 (6.5; 0.8, 21.4) 52 (36.9; 28.9, 45.4) 26 (41.9; 29.5, 55.2) 1535 (18.9; 18, 19.8) 
1 in 150 for PE <40 GW 2 (6.5; 0.8, 21.4) 58 (41.1; 32.9, 49.7) 31 (50.0; 37.0, 63.0) 2032 (25.0; 24.1, 26) 
1 in 200 for PE <40 GW 2 (6.5; 0.8, 21.4) 61 (43.3; 35.0, 51.9) 33 (53.2; 40.1, 66.0) 2481 (30.5; 29.5, 31.5) 
 
Table 2: Stratification of risk for preeclampsia. The numbers in the grey bands represent 
the high-risk group and those in the white bands the intermediate-risk group. Numbers in 
parentheses are percentages with 95% confidence intervals. 
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Table 3. Proportion of the population stratified into high- intermediate- and low-risk groups by combined screening with risk cut-offs of 
1 in 3, 1 in 10, 1 in 50, 1 in 100 and 1 in 150 for preeclampsia (PE) at <4 weeks from assessment and cut-off of 1 in 150 for PE at <37 
weeks’ gestation and the proportion of each strata developing PE with delivery at <4 weeks, at 4w-40GW and at >40GW. 
 
  
 
. 
 
Risk cut off for PE 
Strata Proportion of each strata developing PE with delivery at: No preeclampsia 
(n = 7,894)  Type Size (n=8128) <4 w (n=31)  4 w to 40 GW (n=141) >40 GW (n=62) 
1 in 3 for PE <4w and 
1 in 150 for PE <40 GW 
High 76 (0.9; 0.7, 1.2) 24 (31.6; 21.4, 43.3) 25 (32.9; 22.5, 44.6) 0 (0.0; 0.0, 4.7) 27 (35.5; 24.9, 47.3) 
Intermediate 2325 (28.6; 27.6, 29.6) 7 (0.3; 0.1, 0.6) 101 (4.3; 3.6, 5.3) 42 (1.8; 1.3, 2.4) 2175 (93.5; 92.5, 94.5) 
Low 5727 (70.5; 69.5, 71.5) 0 (0.0; 0.0, 0.1) 15 (0.3; 0.1, 0.4) 20 (0.3; 0.2, 0.5) 5692 (99.4; 99.2, 99.6) 
1 in 10 for PE <4w and 
1 in 150 for PE <40 GW 
High 134 (1.6;1.4, 1.9) 26 (19.4; 13.1, 27.1) 37 (27.6; 20.2, 36.0) 1 (0.7; 0.0, 4.1) 70 (52.2; 43.4, 60.9) 
Intermediate 2267 (27.9; 26.9, 28.9) 5 (0.2; 0.1, 0.5) 89 (3.9; 3.2, 4.8) 41 (1.8; 1.3, 2.4) 2132 (94.0; 93.0, 95.0) 
Low 5727 (70.5; 69.5, 71.5) 0 (0.0; 0.0, 0.1) 15 (0.3; 0.1, 0.4) 20 (0.3; 0.2, 0.5) 5692 (99.4; 99.2, 99.6) 
1 in 50 for PE <4w and 
1 in 150 for PE <40 GW 
High 254 (3.1; 2.8, 3.5) 28 (11.0; 7.5, 15.5) 57 (22.4; 17.5, 28.1) 7 (2.8; 1.1, 5.6) 162 (63.8; 57.5, 69.7) 
Intermediate 2147 (26.4; 25.5, 27.4) 3 (0.1; 0.0, 0.4) 69 (3.2; 2.5, 4.0) 35 (1.6; 1.1, 2.3) 2040 (95.0; 94.0, 95.9) 
Low 5727 (70.5; 69.5, 71.5) 0 (0.0; 0.0, 0.1) 15 (0.3; 0.1, 0.4) 20 (0.3; 0.2, 0.5) 5692 (99.4; 99.2, 99.6) 
1 in 100 for PE <4w and 
1 in 150 for PE <40 GW 
High 314 (3.9; 3.5, 4.3) 28 (8.9; 6.0, 12.6) 64 (20.4; 16.1, 25.3) 8 (2.5; 1.1, 5.0) 214 (68.2; 62.7, 73.3) 
Intermediate 2087 (25.7; 24.7, 26.6) 3 (0.1; 0.0, 0.4) 62 (3.0; 2.3, 3.8) 34 (1.6; 1.1, 2.3) 1988 (95.3; 94.3, 96.1) 
Low 5727 (70.5; 69.5, 71.5) 0 (0.0; 0.0, 0.1) 15 (0.3; 0.1, 0.4) 20 (0.3; 0.2, 0.5) 5692 (99.4; 99.2, 99.6) 
1 in 150 for PE <4 w and 
1 in 150 for PE <40 GW 
High 369 (4.5; 4.1, 5.0) 29 (7.9; 5.3, 11.1) 68 (18.4; 14.6, 22.8) 11 (3.0; 1.5, 5.3) 261 (70.7; 65.8, 75.3) 
Intermediate 2032 (25.0; 24.1, 26.0) 2 (0.1; 0.0, 0.4) 58 (2.9; 2.2, 3.7) 31 (1.5; 1.0, 2.2) 1941 (95.5; 94.5, 96.4) 
Low 5727 (70.5; 69.5, 71.5) 0 (0.0; 0.0, 0.1) 15 (0.3; 0.1, 0.4) 20 (0.3; 0.2, 0.5) 5692 (99.4; 99.2, 99.6) 
